Company intelligence / Profile preview

Keapstone Therapeutics

Sheffield, England, United Kingdomkeapstone.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Keapstone Therapeutics develops CNS penetrant small molecules that activate the Nrf2–ARE pathway by inhibiting the interaction between KEAP1 and Nrf2. This approach aims to provide neuroprotection in diseases like Parkinson’s and ALS by improving redox balance, mitochondrial function, promoting autophagy, and limiting inflammation. The company appears to be in preclinical stages with no reported clinical results yet.

Therapeutic areas: Neurology
Modalities: small molecules
Industry: Biotech

Partnerships

University of Sheffield/SITraN – academic collaboration and access to models for PD/MND researchEuropean Lead Factory – foundational work/funding support

Beyond the preview

Go deeper on Keapstone Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keapstone Therapeutics.

Explore the full profile